Whole genome sequencing

Inocras and Massive Bio Forge Groundbreaking Alliance to Revolutionize Cancer Care with Whole-Genome Insights and Clinical Trial Matching

Retrieved on: 
月曜日, 6月 3, 2024
Biotechnology, Oncology, Health, Artificial Intelligence, Data Management, Technology, Genetics, Clinical Trials, Partner, Biomarker, CLIA, Multimedia, Patient, Ecosystem, Cancer, Medicine, National Cancer Institute, Drug development, Moonshot, Clinical trial, AI, Genetic testing, CAP, M&A, Roger Hawkins (drummer), SBIR, Whole genome sequencing, Partnership, Physician, WGS

Inocras, a leading AI-driven whole genome testing company, and Massive Bio, a cutting-edge AI-driven clinical trial matching platform provider, have joined forces to set a new standard for cancer patient care.

Key Points: 
  • Inocras, a leading AI-driven whole genome testing company, and Massive Bio, a cutting-edge AI-driven clinical trial matching platform provider, have joined forces to set a new standard for cancer patient care.
  • This strategic collaboration leverages Inocras's expertise in whole genome sequencing (WGS) and bioinformatics alongside Massive Bio's advanced AI technology for clinical trial matching, with the shared mission of enhancing personalized care for cancer patients.
  • Given the historically burdensome task of finding suitable clinical trials for cancer patients, partnering with Massive Bio is paramount.
  • Utilizing AI to enhance equitable access and precision targeting for clinical trial matching, drug matching, and drug development, Massive Bio is committed to breaking down barriers in clinical trial enrollment, fostering value-based oncology decisions, and facilitating data-driven cancer treatment.

New Blood Test Predicts Recurrence of Breast Cancer, Months or Even Years Before Relapse

Retrieved on: 
日曜日, 6月 2, 2024
Science, Biotechnology, Research, Surgery, Oncology, Health, Genetics, Clinical Trials, Breast cancer, ASCO, Institute of Cancer Research, NHS foundation trust, Patient, Cell, Ultra, Cancer, The Institute, Exon, Society, DNA, Chief Justice of Hungary, Molecular oncology, MRD, Genome, Sequence, Woman, WES, Recurrence, Risk, Disease, Blood, ICR, Gene, Breast, Diagnosis, Whole genome sequencing, Weapon, Survival, Neoplasm, WGS, Medical imaging

A new type of blood test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research has shown.

Key Points: 
  • A new type of blood test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research has shown.
  • Blood samples from 78 patients with different types of early breast cancer (23 with triple negative breast cancer, 35 with HER2+ breast cancer, 18 with hormone receptor+ breast cancer and two with an unknown subtype) were screened for ctDNA.
  • The median lead time to clinical relapse in this group of patients was 15 months, an increase of over three months, compared with other ctDNA tests in all types of breast cancer.
  • The study shows the importance and promise of using an ultra-sensitive MRD test like NeXT Personal to detect the earliest traces of breast cancer recurrence, and more optimally guide management of breast cancer patients.”

Inocras Presents Poster for Breast Cancer at 2024 ASCO Annual Meeting, Showing Transformative Impact of WGS-based HRD Testing

Retrieved on: 
土曜日, 6月 1, 2024
Oncology, Data Management, Health, Technology, Health Technology, Genetics, Biotechnology, Patient, ADP, Breast MRI, Inc., BRCA2, MRI, Breast cancer, Whole genome sequencing, Samsung Medical Center, MRD, WGS, Research, Breast, Cancer, Medicine, Biomarker, ASCO, Gene, BRCA1, Hospital, Woman, Society, DCE, Multimedia, HRD, Annual general meeting, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20240531817764/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240531817764/en/
    In collaboration with Samsung Medical Center and St. Mary’s Hospital, Inocras' research study recruited 145 women with invasive breast cancer.
  • Researchers utilized dynamic contrast-enhanced (DCE) breast MRI to explore the relationship between HRD and specific radiomic features.
  • HRD, a crucial target in breast cancer treatment, involves key genes known as BRCA1 and BRCA2, whose pathogenic mutations are crucial features for selecting poly (ADP-ribose) polymerase inhibitors (PARPi) treatment.
  • “This research underscores the transformative impact of WGS-based HRD testing, allowing for a more comprehensive view of HRD and the development of better evaluation and screening tools,” said Inocras co-founder Jeong Seok Lee.

Tempus Announces the Clinical Launch of its MRD Testing Portfolio

Retrieved on: 
金曜日, 5月 31, 2024
Oncology, Health, Hospitals, Genetics, Health Technology, Biotechnology, Chief Justice of Hungary, Genomics, Patient, DNA, Plasma, Intelligence, NeXT, Machine learning, Algorithm, Recurrence, Lung cancer, Rated R, Breast cancer, NSCLC, Whole genome sequencing, Neoplasm, MD, MRD, Blood, ADJ, Research, DX, ASCO, DFS, CRC, Medicine, CEA, Immunotherapy, Physician, Annual general meeting, Medical imaging

Tempus, a leader in artificial intelligence and precision medicine, today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM test and the xM (NeXT Personal® Dx) test by Personalis.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM test and the xM (NeXT Personal® Dx) test by Personalis.
  • The addition of both assays further complements Tempus’ comprehensive testing portfolio.
  • Tempus introduced its first MRD test, xM MRD, for research use in January 2024.
  • “MRD testing is the perfect complement to our comprehensive testing portfolio, as we are now equipping physicians with a proactive solution that provides early-stage cancer insights for their patients that is critical to their care,” said Halla Nimeiri, MD, Chief Development Officer at Tempus.

QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision medicine

Retrieved on: 
水曜日, 5月 29, 2024
Singular, NGS, Genomics, Proteomics, DNA, Metagenomics, QGEN, Epigenomics, Chemistry, Drug development, Whole genome sequencing, Senior, Blood, WGS, Research, Cancer, WES, Biomarker, Workflow, Completeness, Medicine, RNA, Papillomaviridae, Library, QIAGEN, WTS, Sequence, Nucleic acid thermodynamics, Vaccine

The kit offers a streamlined and rapid workflow to generate WGS and WTS libraries from a single sample by combining chemistry optimized for DNA and RNA simultaneously.

Key Points: 
  • The kit offers a streamlined and rapid workflow to generate WGS and WTS libraries from a single sample by combining chemistry optimized for DNA and RNA simultaneously.
  • Using traditional methods, separate workflows for DNA and RNA sequencing require a large amount of sample material, labor-intensive library preparation procedures, and long turn-around times.
  • With a focus on front-end sample processing and downstream bioinformatics, QIAGEN provides innovative NGS technologies for genomics, transcriptomics, epigenomics, and metagenomics applications.
  • QIAGEN’s QIAseq kits have processed over four million NGS samples, enabling biomarker research, gene expression studies, viral epidemiology, and disease surveillance.

CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
水曜日, 5月 15, 2024
TWIST, IVDR, Partnership, Hereditary angioedema, DSM-IV codes, LRRK2, Genetic testing, Software, Cancer, Parkinsonism, Total, European, Drug discovery, RNA, Twist Bioscience, Disclosure, Mox, Niemann–Pick disease, CLN6, Sale, Whole genome sequencing, Publication, Epilepsy, Physician, Frontotemporal dementia, DNA sequencing, JV, CFTR, FTD, Elbow method (clustering), Disease, CNTG, Research, Observational study, Patient, Genetics, Gulf Cooperation Council, Sequence, CE, DNA, Therapy, Acyl-CoA, Software as a service, GCC, Growth, Gaucher's disease, Spinal muscular atrophy, Fine chemical

and ROSTOCK, Germany and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided a business update.

Key Points: 
  • and ROSTOCK, Germany and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided a business update.
  • We expanded our partnership model with a joint venture in Saudi Arabia, securing a $30 million investment and additional milestone payments.
  • With this progress at the forefront, CENTOGENE is positioned for growth and a path towards profitability.
  • There can be no assurance that our strategic review process will result in any transaction or other strategic outcome.

Inocras and IMBdx Announce Strategic Partnership to Transform Cancer Patient Care in the U.S.

Retrieved on: 
水曜日, 5月 22, 2024
Oncology, Data Management, Health, Technology, Health Technology, Genetics, Biotechnology, Partnership, Patient, Genetic testing, Disease, Whole genome sequencing, WGS, Cancer, Biomarker, Liquid biopsy, Multimedia, Medical imaging

Inocras and IMBdx have announced a partnership aimed at enhancing care for cancer patients in the U.S.

Key Points: 
  • Inocras and IMBdx have announced a partnership aimed at enhancing care for cancer patients in the U.S.
  • Through this partnership, Inocras, a leader in whole genome sequencing diagnostics, and IMBdx, an innovator in liquid biopsy-based diagnostics for cancer, will be able to provide broader offerings for cancer patients and their providers.
  • View the full release here: https://www.businesswire.com/news/home/20240522093513/en/
    Inocras specializes in cancer profiling using whole genome sequencing (WGS), capturing over 99% of an individual's genomic makeup.
  • "Our collaboration with IMBdx marks a significant step forward in our mission to transform healthcare for cancer and rare disease patients," said Jehee Suh, CEO of Inocras.

BGI-HL OHA Lab inaugurated in Harbin, initiating colorectal cancer risk assessment for 800,000

Retrieved on: 
月曜日, 5月 13, 2024
BGI Group, Lab, Colorectal cancer, Conditional sentence, Urine, Health, Public, Whole genome sequencing, Large intestine, Cancer, World Health Organization, Death, CRC, Medicine, Genomics

With detailed health and disease risk profiles, it sets the stage for breakthroughs in early detection and personalized treatment, critical tenets of precision medicine.

Key Points: 
  • With detailed health and disease risk profiles, it sets the stage for breakthroughs in early detection and personalized treatment, critical tenets of precision medicine.
  • Colorectal cancer, a focal point of the Lab's research, is ranked as the third most common cancer worldwide and the second leading cause of cancer-related deaths.
  • This large-scale public health effort exemplifies the Lab's commitment to precision medicine, tailored to combat public health issues more effectively.
  • This facility is committed to advancing Heilongjiang's digital and biotech ecosystem and contributing to public health improvements by applying the latest life science technologies.

BGI-HL OHA Lab inaugurated in Harbin, initiating colorectal cancer risk assessment for 800,000

Retrieved on: 
月曜日, 5月 13, 2024
BGI Group, Lab, Colorectal cancer, Conditional sentence, Urine, Health, Public, Whole genome sequencing, Large intestine, Cancer, World Health Organization, Death, CRC, Medicine, Genomics, Multimedia

With detailed health and disease risk profiles, it sets the stage for breakthroughs in early detection and personalized treatment, critical tenets of precision medicine.

Key Points: 
  • With detailed health and disease risk profiles, it sets the stage for breakthroughs in early detection and personalized treatment, critical tenets of precision medicine.
  • Colorectal cancer, a focal point of the Lab's research, is ranked as the third most common cancer worldwide and the second leading cause of cancer-related deaths.
  • The laboratory's first significant initiative involves assessing colorectal cancer risks for nearly 800,000 eligible for screening (45-64-year-old residents), employing gene methylation technology for early detection and preventive care.
  • This large-scale public health effort exemplifies the Lab's commitment to precision medicine, tailored to combat public health issues more effectively.

CIRM Awards $11.8 Million Grant for Clinical Trial in High-Grade Glioma Including Glioblastoma Using DB107, a Novel DGM7™ Genetic Biomarker-Guided Gene Therapy

Retrieved on: 
火曜日, 4月 30, 2024
University of Southern California, Efficacy, University, UCSD, Radiation, Resection, Regenerative medicine, HGG, TMZ, Doctor of Philosophy, RRV, GBM, WGS, Glioblastoma, Artificial intelligence, Depression, CIRM, UCSF, USC, Intravenous therapy, Neoplasm, Clinical trial, Medicine, SHROOM3, Whole genome sequencing, SAN, Medical imaging

We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.

Key Points: 
  • We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.
  • DB107 consists of two components: DB107–RRV (vocimagene amiretrorepvec) as a prodrug activator gene therapy and DB107–FC (extended-release 5–fluorocytosine [5–FC]) as an oral prodrug.
  • Retrospective analysis of an earlier randomized clinical trial in patients with recurrent HGG suggested improved overall survival in DGM7–positive patients treated with DB107.
  • "We are excited to conduct this novel trial which will be investigating several new approaches for the first time in patients with newly–diagnosed high–grade glioma.